IMI launches €130 million calls for proposals

On 19 July, the Innovative Medicines Initiative (IMI) launched two new Calls for proposals (Call 11 and Call 12) with topics regarding Alzheimer’s disease, big data, vaccines, autoimmune disease, the blood-brain barrier, drug development, and the exploitation of IMI project results with a total budget of over € 130 million.

Here an overview of the topics covered:

IMI2 – Call 11

  • One topic on ‘Exploitation of IMI project results’

Deadline for submission of proposals: 24 October 2017

More information on the topics, their conditions and key dates can be found here.  

IMI2 – Call 12
  • Topic 1: Development and validation of technology enabled, quantitative and sensitive measures of functional decline in people with early stage Alzheimer’s disease (RADAR-AD)
  • Topic 2: FAIRification of IMI and EFPIA data
  • Topic 3: Development of sensitive and validated clinical endpoints in primary Sjögren’s Syndrome (pSS)
  • Topic 4: European Health Data Network (EHDN)
  • Topic 5: Analysing the infectious disease burden and the use of vaccines to improve healthy years in aging populations
  • Topic 6: Discovery and characterisation of blood-brain barrier targets and transport mechanisms for brain delivery of therapeutics to treat neurodegenerative & metabolic diseases
  • Topic 7: European Screening Centre: unique library for attractive biology (ESCulab)

Deadline for submission of proposals: 24 October 2017

More information on the topics, their conditions and key dates can be found here.  

Background

  • IMI is a partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA).
  • Through the IMI 2 programme, IMI has a budget of €3.3 billion for the period 2014-2024. Half of this comes from the EU’s research and innovation programme, Horizon 2020. The other half comes from large companies, mostly from the pharmaceutical sector; these do not receive any EU funding, but contribute to the projects ‘in kind’, for example by donating their researchers’ time or providing access to research facilities or resources.



Date: 03/08/2017 | Tag: | News: 638 of 709
All news

News

More news

Events

More events
newsletter

Subscribe to the VPH Institute Newsletter

Are you...

A clinician?
A researcher?
A science curious?
An industrial?

Open subscribe Reduce

ARCHIVE

Read all the newsletters of the VPH Institute

GO